Physician profile

Wayne A Hey

Urology · Fort Worth, TX

NPI 1851354914

$2,720.23

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$203.08
Education$99.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Coloplast Corp $1,809.70 2019-2024 Speedicath
Astellas Pharma US INC $409.24 2019-2023 Myrbetriq
Janssen Biotech, INC. $202.92 2022-2023 Erleada
Urovant Sciences INC $109.78 2021
Boston Scientific Corporation $73.09 2022-2024 Lithovue
Blue Earth Diagnostics $50.46 2019-2020
Abbvie INC. $19.92 2021
Neotract INC. $16.25 2019
Pfizer INC. $14.55 2019
Cook Medical LLC $14.32 2023 Resonance

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Wayne A Hey

$2,720.23

in general payments reported 2019-2025

Years
2019-2024
Top company
Coloplast Corp

https://glasscript.com/doctor/83565/wayne-a-hey

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.